Potential Therapeutic Aspects of Alarmin Cytokine Interleukin 33 or Its Inhibitors in Various Diseases

Arshad, Muhammad; Khan, Hayat Ahmad; Noel, G. R.; Piquet‐Pellorce, Claire; Samson, Michel

doi:10.1016/j.clinthera.2016.02.021

Cited by 23 publications

(17 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, also other cytokine trap proteins, such as the recently described TSLPtrap, 47 might be interesting leads. The IL-33/ ST2 axis has also been implicated in various other non-T H 2 diseases, such as rheumatoid arthritis, colitis, multiple sclerosis, lupus, age-related macular degeneration, fibrosis, and disorders of the central nervous system, 4,48 implicating that the effect of our IL-33trap technology might be much broader than allergic diseases. Given the apparent diverse roles of IL-33 in a multitude of processes, manipulation of IL-33 signaling might be highly disease dependent.…”

Section: Discussionmentioning

confidence: 99%

IL-33trap is a novel IL-33–neutralizing biologic that inhibits allergic airway inflammation

Holgado

Braun

Nuffel

et al. 2019

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

IL-33trap is a novel IL-33–neutralizing biologic that inhibits allergic airway inflammation

Holgado

Braun

Nuffel

et al. 2019

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Some studies have shown contrasting roles of IL-33 in bone remodeling. As reported by some authors, IL-33 stops osteoclast formation from bone marrow precursor cells [99], while others showed IL-33 shifting the equilibrium in vitro from osteoclasts to the differentiation of alternatively activated macrophages [100]. A reduction in osteoprotegerin expression mediated by osteoblasts and an increase in osteoclastogenic factor release inducing bone resorption during inflammation mediated by IL-33 was proposed [101], even though some in vitro evidence suggests that IL-33 stimulates matrix mineralization [102].…”

Section: Il-33mentioning

confidence: 98%

Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review

et al. 2020

View full text Add to dashboard Cite

Alarmins are endogenous mediators released by cells following insults or cell death to alert the host’s innate immune system of a situation of danger or harm. Many of these, such as high-mobility group box-1 and 2 (HMGB1, HMGB2) and S100 (calgranulin proteins), act through RAGE (receptor for advanced glycation end products), whereas the IL-1 and IL-33 cytokines bind the IL-1 receptors type I and II, and the cellular receptor ST2, respectively. The alarmin family and their signal pathways share many similarities of cellular and tissue localization, functions, and involvement in various physiological processes and inflammatory diseases including osteoporosis. The aim of the review was to evaluate the role of alarmins in osteoporosis. A bibliographic search of the published scientific literature regarding the role of alarmins in osteoporosis was organized independently by two researchers in the following scientific databases: Pubmed, Scopus, and Web of Science. The keywords used were combined as follows: “alarmins and osteoporosis”, “RAGE and osteoporosis”, “HMGB1 and osteoporosis”, “IL-1 and osteoporosis”, “IL 33 and osteopororsis”, “S100s protein and osteoporosis”. The information was summarized and organized in the present review. We highlight the emerging roles of alarmins in various bone remodeling processes involved in the onset and development of osteoporosis, as well as their potential role as biomarkers of osteoporosis severity and progression. Findings of the research suggest a potential use of alarmins as pharmacological targets in future therapeutic strategies aimed at preventing bone loss and fragility fractures induced by aging and inflammatory diseases.

show abstract

“…There is enough evidence to show upregulated IL-33 expression by astrocytes and peripheral leukocytes in MS patients (64). Although it has been found that IL-33 induces pro-inflammatory type-2 responses, the anti-inflammatory properties of this cytokine have been thought to be beneficial in autoimmunity (65,66) as well as in many other disorders (67).…”

Section: Discussionmentioning

confidence: 99%

Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis

Alsahebfosoul

Rahimmanesh

Shajarian

et al. 2017

Biomolecular Concepts

View full text Add to dashboard Cite

Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders. In a case-control study, venous blood was collected from healthy subjects categorized as control group (n = 44) and MS patients (n = 44). All recruited patients were clinically diagnosed with relapsing-remitting MS (RRMS), including patients without treatment (new identified cases, n = 16) and those treated with interferon beta (IFN-β) (n = 28). The plasma levels of IL-33 in subjects were measured with ELISA. Significantly elevated IL-33 plasma levels were observed in RRMS patients (p = 0.005). Furthermore, IFN-β-treated MS patients had lower levels of IL-33 compared to the untreated patients (p < 0.001). Increased IL-33 plasma levels in the patient group might be associated with development of MS. These results could contribute to our better understanding about the role of IL-33 in the immunopathogenesis of MS.

show abstract

Potential Therapeutic Aspects of Alarmin Cytokine Interleukin 33 or Its Inhibitors in Various Diseases

Cited by 23 publications

References 85 publications

IL-33trap is a novel IL-33–neutralizing biologic that inhibits allergic airway inflammation

IL-33trap is a novel IL-33–neutralizing biologic that inhibits allergic airway inflammation

Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review

Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis

Contact Info

Product

Resources

About